I will now need to step in and provide expertise like I did last year when I had to correct the no problemo assertion about the Bioharp BS saga (no problemo, of course, was very wrong regarding the Bioharp BS) Until Lisenby demonstrates the ability to accomplish something substantive, the stock goes nowhere - This is a very big problem for shareholders.
News 
Market Data 
Discover 
AI
